Table 1.

Characteristics of the Participants

Variable	Overall		Nonmetastatic Disease						Advanced Metastatic Disease
			Before Adjuvant Therapy		During Adjuvant Therapy		After Adjuvant Therapy
	No.	%	No.	%	No.	%	No.	%	No.	%
No. of patients	248	100	20	8	46	19	130	52	52	21
Site
Canada	201	81	20	100	19	41	130	100	52	100
United States	47	19	—		27	59	—		—
Age, years
Mean	55		49		53		57		55
SD	8		9		7		8		10
Range	30-74		30-61		40-70		31-73		36-74
Weight, kg
Mean	76		78		75		77		70
SD	17		19		16		17		16
BMI, kg/m2
Mean	28		29		28		29		27
SD	6		7		6		6		5
Range	16-50		18-46		18-40		16-50		18-45
KPS
70	3	1	—		—		—		3	6
75	1	< 1	—		—		—		1	2
80	6	2	—		—		—		6	12
90	43	17	—		13	28	—		30	60
100	193	78	20	100	33	72	130	100	10	20
Exercise behavior, min·wk−1
Mean	222		135		199		270		172
SD	269		171		275		307		192
Meeting ACSM guidelines*	49	25	5	25	3	11	32	31	9	18
Time from primary diagnosis, months
Mean	21		1		7		27		25
SD	19		0.4		6		16		26
Anatomic stage
IA	37	15	1	5	6	13	30	23	—
IB	37	15	4	20	3	7	30	23	—
IIA	52	21	12	60	18	39	22	17	—
IIB	43	17	2	10	11	24	30	23	—
IIIA	25	10	1	5	7	15	17	13	—
IIIB	1	< 1	—		1	2	—		—
IIIC	1	< 1	—		—		1	1	—
IV	51	21	—		—		—		52	100
Current cytotoxic therapy			NA				NA
Chemotherapy	63	64			29	63			34	65
Anthracycline-containing regimen	43	68			29	100			14	41
Trastuzumab	29	30			17	37			12	23
Radiation	20	20			0	0			20	38
Prior primary cytotoxic therapy			NA		NA
Chemotherapy	128	70					96	74	32	62
Anthracycline-containing regimen	79	62					62	65	17	53
Trastuzumab	18	10					18	14	0	0
Radiation	127	70					102	78	25	48

Abbreviations: ACSM, American College of Sports Medicine; BMI, body mass index; KPS, Karnofsky performance status; NA, not applicable; SD, standard deviation.

^*ASCM guidelines defined as percentage of patients reporting ≥ 150 minutes · wk⁻¹ of at least moderate and/or strenuous exercise.